Premium
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
VANCOUVER, British Columbia, Feb. 10, 2021 -- InvestorsHub NewsWire -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or...
VANCOUVER, British Columbia, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage...
Algernon Receives U.S. FDA Clearance for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19 VANCOUVER, British Columbia, June 04, 2020...
Algernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) Howard Gutman to Advisory Board VANCOUVER, British Columbia, Canada...
Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency Use VANCOUVER, British Columbia, Canada -- March 13, 2020...
Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus VANCOUVER, British Columbia, Canada -- March 6, 2020 -- InvestorsHub NewsWire -- Algernon...
Algernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) Exhibited Potent Anti-Fibrotic Activity in NASH and CKD...
Algernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis in a Recent Idiopathic Pulmonary Fibrosis Study by...
Algernon Pharmaceuticals’ NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56% Outperforming USFDA Approved Treatments...
#outlook a {padding:0;} body {width:100%; -webkit-text-size-adjust:100%; -ms-text-size-adjust:100%; margin:0; padding:0;} .ReadMsgBody {width:100%;} .ExternalClass...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.08 | 0.095 | 0.075 | 19113 | 0.07974886 | CS |
| 4 | 0.005 | 6.66666666667 | 0.075 | 0.095 | 0.065 | 31103 | 0.07889514 | CS |
| 12 | -0.005 | -5.88235294118 | 0.085 | 0.1 | 0.06 | 33760 | 0.07579474 | CS |
| 26 | -0.04 | -33.3333333333 | 0.12 | 0.1325 | 0.06 | 26071 | 0.08508109 | CS |
| 52 | 0.005 | 6.66666666667 | 0.075 | 0.165 | 0.06 | 27299 | 0.10046681 | CS |
| 156 | -1.8325 | -95.8169934641 | 1.9125 | 2.0925 | 0.05 | 18284 | 0.2065753 | CS |
| 260 | 0.0625 | 357.142857143 | 0.0175 | 2.975 | 0.01125 | 327761 | 0.07829736 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
